---
title: "Marker Therapeutics, Inc. (MRKR.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/MRKR.US.md"
symbol: "MRKR.US"
name: "Marker Therapeutics, Inc."
industry: "Biotechnology"
datetime: "2026-04-16T22:37:17.302Z"
locales:
  - [en](https://longbridge.com/en/quote/MRKR.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/MRKR.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/MRKR.US.md)
---

# Marker Therapeutics, Inc. (MRKR.US)

## Company Overview

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets. It develops MT-601, which is in Phase 1 trials for the treatment of lymphoma and pancreatic cancer; and MT-401-OTS, which is in a Phase 1 trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes. The company was formerly known as TapImmune, Inc.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [markertherapeutics.com](https://markertherapeutics.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-04-16T04:30:17.000Z

**Overall: D (0.67)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 313 / 393 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -46.19% |  |
| Net Profit YoY | -13.35% |  |
| P/B Ratio | 1.57 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 26343540.66 |  |
| Revenue | 3546669.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -68.81% | E |
| Profit Margin | -342.96% | E |
| Gross Margin | -232.68% | E |
| Revenue YoY | -46.19% | E |
| Net Profit YoY | -13.35% | D |
| Total Assets YoY | -13.40% | E |
| Net Assets YoY | -9.49% | D |
| Cash Flow Margin | 98.77% | C |
| OCF YoY | -46.19% | E |
| Turnover | 0.17 | D |
| Gearing Ratio | 11.92% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Marker Therapeutics, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-46.19%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-13.35%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.57",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "26343540.66",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "3546669.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-68.81%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-342.96%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-232.68%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "-46.19%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-13.35%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "-13.40%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-9.49%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "98.77%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-46.19%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.17",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "11.92%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -2.17 | 260/393 | - | - | - |
| PB | 1.57 | 140/393 | 1.36 | 1.23 | 1.07 |
| PS (TTM) | 7.43 | 138/393 | 5.33 | 3.04 | 2.22 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Rigel Pharma (RIGL.US) | A | A | B | B | B | A |
| 03 | MiMedx (MDXG.US) | A | B | A | B | B | A |
| 04 | Vertex Pharma (VRTX.US) | A | B | C | B | C | B |
| 05 | Regeneron Pharma (REGN.US) | A | C | C | B | C | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-03-20T04:00:00.000Z

Total Analysts: **3**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 3 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 1.61 |
| Highest Target | 10.00 |
| Lowest Target | 5.60 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/MRKR.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/MRKR.US/norm.md)
- [Related News](https://longbridge.com/en/quote/MRKR.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/MRKR.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**